文献速递哮喘

支气管热成形术治疗重度哮喘5年随访:PAS2研究

Bronchial Thermoplasty in Patients With Severe Asthma at 5 Years: The Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma Study.
PubMed 文献 · Chest · 2021-11-10

PAS2研究为前瞻性、开放标签、观察性、多中心研究,纳入284例重度哮喘患者,227例完成5年随访。结果显示,治疗后第5年重度急性发作、急诊就诊和住院比例分别为42.7%、7.9%和4.8%,均低于治疗前12个月的77.8%、29.4%和16.1%。维持口服糖皮质激素比例从基线19.4%降至5年时9.7%,所有亚组均显示临床显著改善。

要点

  • 5年时重度急性发作比例42.7%,低于治疗前12个月的77.8%。
  • 维持口服糖皮质激素比例从基线19.4%降至5年时9.7%。
  • 所有基于基线临床和生物标志物的亚组均显示临床显著改善。

核心结论

  • 支气管热成形术后5年,重度哮喘患者的重度急性发作、住院、急诊就诊和糖皮质激素暴露均减少。
  • 所有亚组均显示临床显著改善,提示支气管热成形术可改善不同哮喘表型的哮喘控制。

研究设计与样本

  • 前瞻性、开放标签、观察性、多中心研究,在美国和加拿大开展。
  • 纳入18至65岁、使用吸入糖皮质激素≥1000 μg/d(倍氯米松或等效剂量)和长效β2受体激动剂≥80 μg/d(沙美特罗或等效剂量)的重度哮喘患者。
  • 共284例受试者在27个中心入组,227例(80%)完成5年随访。

主要发现

  • 治疗后第5年,重度急性发作、急诊就诊和住院的比例分别为42.7%、7.9%和4.8%。
  • 治疗前12个月,重度急性发作、急诊就诊和住院的比例分别为77.8%、29.4%和16.1%。
  • 维持口服糖皮质激素的患者比例从基线19.4%降至5年时9.7%。
  • 基于基线临床和生物标志物的亚组分析显示所有亚组均有统计学显著的临床改善。

临床怎么用

  • 对于使用高剂量吸入糖皮质激素和长效β2受体激动剂仍控制不佳的重度哮喘患者,支气管热成形术可作为改善长期哮喘控制的治疗选择。
  • 术后5年随访数据显示该治疗可减少重度急性发作、急诊就诊、住院和口服糖皮质激素暴露。

局限性

  • 本研究为开放标签、观察性研究,未设对照组。
  • 284例入组受试者中227例(80%)完成5年随访,存在失访偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bronchial thermoplasty is a device-based treatment for subjects ≥ 18 years of age with severe asthma poorly controlled with inhaled corticosteroids and long-acting beta-agonists. The Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma (PAS2) study collected data on patients with severe asthma undergoing this procedure. RESEARCH QUESTION: What are the 5-year efficacy and safety results in patients with severe asthma who have undergone bronchial thermoplasty? STUDY DESIGN AND METHODS: This was a prospective, open-label, observational, multicenter study conducted in the United States and Canada. Subjects 18 to 65 years of age who were taking inhaled corticosteroids ≥ 1,000 μg/d (beclomethasone or equivalent) and long-acting beta-agonists ≥ 80 μg/d (salmeterol or equivalent) were included. Severe exacerbations, hospitalization, ED visits, and medication usage were evaluated for the 12 months prior to and at years 1 through 5 posttreatment. Spirometry was evaluated at baseline and at years 1 through 5 posttreatment. RESULTS: A total of 284 subjects were enrolled at 27 centers; 227 subjects (80%) completed 5 years of follow-up. By year 5 posttreatment, the proportion of subjects with severe exacerbations, ED visits, and hospitalizations was 42.7%, 7.9%, and 4.8%, respectively, compared with 77.8%, 29.4%, and 16.1% in the 12 months prior to treatment. The proportion of subjects on maintenance oral corticosteroids decreased from 19.4% at baseline to 9.7% at 5 years. Analyses of subgroups based on baseline clinical and biomarker characteristics revealed a statistically significant clinical improvement among all subgroups. INTERPRETATION: Five years after treatment, subjects experienced decreases in severe exacerbations, hospitalizations, ED visits, and corticosteroid exposure. All subgroups demonstrated clinically significant improvement, suggesting that bronchial thermoplasty improves asthma control in different asthma phenotypes. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT01350336; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Chupp G, Kline JN, Khatri SB, et al. Bronchial Thermoplasty in Patients With Severe Asthma at 5 Years: The Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma Study. Chest. 2021. PMID: 34774528. doi:10.1016/j.chest.2021.10.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。